Drug Profile
Research programme: controlled-release pain therapeutics - Avadel Pharmaceuticals
Alternative Names: Trigger Lock therapeutics - Avadel PharmaceuticalsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Flamel Technologies
- Developer Avadel Pharmaceuticals
- Class Opioid analgesics
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in France (PO, Controlled release)
- 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
- 17 Oct 2011 Preclinical development is ongoing in France